Systemic Lupus Erythematosus (SLE), Vasculitis
Conditions
Keywords
Complement, C5aR, Vascular diseases, Cardiovascular diseases
Brief summary
The primary objective of this study will be to evaluate the safety and tolerability of single and multiple oral doses of CCX168, over a range of dose levels, in healthy male and female participants.
Interventions
DRUGCCX168
Administered orally.
DRUGPlacebo
Administered orally.
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female participants, aged 19-45 years inclusive, who are in generally good health, whose body mass index is 19 to 29 kg/m\^2; * Willing and able to give written Informed Consent and to comply with the requirements of the study protocol; * Negative result of the human immunodeficiency virus screen, the hepatitis B screen, and the hepatitis C screen; * Judged to be healthy by the Investigator, based on medical history, physical examination (including ECG), and clinical laboratory assessments. Participants with clinical laboratory values that are outside of normal limits and/or with other abnormal clinical findings that are judged by the Investigator not to be of clinical significance may be entered into the study, and * Female participants of childbearing potential, and male participants with partners of childbearing potential, may participate if adequate contraception is used during, and for at least the four weeks after, any administration of study medication.
Exclusion criteria
* Women who are pregnant, breastfeeding, or have a positive serum pregnancy test at Screening and/or on Study Day -1; * Expected requirement for use of any medication (with the exception of continuing use by female participants of hormonal contraceptives in accordance with a regimen that has been stable for at least the three months prior to Screening) during the study period; * History within the three months prior to study entry of use of tobacco and/or nicotine containing products; * History within one year prior to study entry of illicit drug use; * History of alcohol abuse at any time in the past; * History of any form of cancer; * Consumed alcoholic beverages, or any food or drink containing grapefruit or grapefruit juice within 24 hours of screening; * History or presence of any medical condition or disease which, in the opinion of the Investigator, may place the participant at unacceptable risk for study participation; * Donated or lost more than 350 mL of blood or blood products within 56 days prior to Screening, or donated plasma within 7 days of randomization; * Participant's hemoglobin less than 12 g/dL (or less than 7.45 mmol/L); * Participated in any clinical study of an investigational product within 30 days prior to randomization; * Participant has any evidence of hepatic disease; aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, or bilirubin \> 1.5 x the upper limit of normal; * Participant has any evidence of renal impairment; serum creatinine \> 1.5 x upper limit of normal, and * Participant's urine tested positive at Screening and/or on Study Day -1 for any of the following: opioids, amphetamines, cannabinoids, benzodiazepines, barbiturates, cocaine, cotinine, or alcohol (Breathalyzer test allowed for alcohol).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | Up to 43 days |
| Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters | Up to 29 days |
| Number of Participants Experiencing Clinically Significant Changes in Electrocardiogram (ECG) Parameters | Up to 29 days |
| Number of Participants Experiencing Clinically Significant Changes in Vital Sign Parameters | Up to 29 days |
Secondary
| Measure | Time frame |
|---|---|
| Apparent Oral Clearance of CCX168 | Period 1: Up to Day 8; Period 2: Up to Day 15 |
| Apparent Volume of Distribution of CCX168 | Period 1: Up to Day 8; Period 2: Up to Day 15 |
| Area Under the Plasma Concentration-time Curve (AUC) of CCX168 From Time 0 to Time t | Period 1: Up to Day 8; Period 2: Up to Day 15 |
| AUC of CCX168 From Time 0 to Infinity | Period 1: Up to Day 8; Period 2: Up to Day 15 |
| AUC of CCX168 From Time 0 to 24 Hours | Periods 1 and 2: Up to Hour 24 |
| Maximum Plasma Concentration (Cmax) of CCX168 | Period 1: Up to Day 8; Period 2: Up to Day 15 |
| AUC of CCX168 From Time 12 to 24 Hours | Periods 1 and 2: Hour 12 to Hour 24 |
| Period 2: AUC of CCX168 From Time 0 to the end of the Dosing Interval | Cohorts 1-3: Up to Hour 24; Cohorts 4-5: Up to Hour 12 |
| Period 2: Accumulation Ratio of CCX168 | Up to Day 7 |
| Percent Inhibition of complement 5a receptor (C5aR)-dependent Upregulation of CD11b in Peripheral Blood Neutrophils | Period 1: Up to Hour 24; Period 2: Up to 12 hours after the first dose on Day 7 |
| AUC of CCX168 From Time 0 to 12 Hours | Periods 1 and 2: Up to Hour 12 |
| Time of Cmax of CCX168 | Period 1: Up to Day 8; Period 2: Up to Day 15 |
| Terminal Phase Rate Constant of CCX168 | Period 1: Up to Day 8; Period 2: Up to Day 15 |
| Apparent Terminal Half-life of CCX168 | Period 1: Up to Day 8; Period 2: Up to Day 15 |
Countries
Switzerland
Outcome results
None listed